TB-500 and Epidermolysis Bullosa Research: The RGN-137 Clinical Trial History

Q: Could injectable TB-500 help someone with epidermolysis bullosa?

There is no research supporting that. The EB trials used a topical gel formulation of full-length Tb4 applied directly to wounds under clinical supervision, not an injected fragment. EB is also a serious genetic condition requiring management by specialists experienced with the disease, not a self-directed research protocol.

Q: What makes the EB trial data more notable than most TB-500 research?

It is one of the few places in the entire thymosin beta-4 literature where a product actually reached human clinical trials in the specific patient population it is meant to help, and advanced far enough to receive FDA clearance for a large Phase 3 design. Most TB-500-related research discussed elsewhere is still animal or cell-culture work.

Q: Why would a peptide studied for tendons and skin also be relevant to a genetic skin disease?

Because EB's core clinical problem, skin that blisters and fails to heal normally from routine friction, is fundamentally a wound-healing problem even though its root cause is genetic rather than traumatic. Any compound with a documented effect on keratinocyte migration and inflammation was a logical candidate to test in a disease defined by chronic, non-healing wounds.

> Research disclaimer: This article discusses published clinical trial history for a topical thymosin beta-4 drug candidate in epidermolysis bullosa, for informational purposes only. TB-500 is sold as a research chemical, is not FDA-approved for any use, and is not the same product studied in the trials described here. Nothing in this article is medical advice, and epidermolysis bullosa is a serious genetic condition that requires management by a physician or specialized wound-care team.

What Is Epidermolysis Bullosa, and Why Was Thymosin Beta-4 Studied For It?

Epidermolysis bullosa (EB) is a group of rare genetic disorders in which the skin — and often mucous membranes — blisters and tears from minor friction or trauma that wouldn't affect intact skin at all. The underlying defect is in one of the proteins that anchor the epidermis to the layer beneath it; depending on which protein is affected, EB is classified as simplex, junctional, or dystrophic, with junctional and dystrophic forms generally producing more severe, harder-to-heal wounds. People with more severe forms of EB live with chronic, recurring open wounds for most of their lives, which makes any therapy that meaningfully speeds wound closure clinically significant in a way that goes beyond cosmetic improvement.

That chronic-wound burden is exactly why thymosin beta-4 (Tβ4) — the full-length protein that TB-500 is a synthetic fragment of — drew interest from EB researchers. Tβ4's documented effects on keratinocyte migration and reduced inflammation, the same mechanisms behind its general wound healing research, made it a plausible candidate for a disease defined almost entirely by wounds that won't close on a normal timeline.

---

RGN-137: The Drug Candidate Behind the Trials

The clinical program used RGN-137, a topical hydrogel formulation developed by RegeneRx Biopharmaceuticals containing a low concentration (around 0.03%) of full-length recombinant Tβ4. This is the same underlying molecule and delivery approach — a topical gel rather than an injection — used in RegeneRx's pressure ulcer and venous stasis ulcer trials; see our pressure ulcer and venous stasis ulcer clinical trials guide for that separate chronic-wound program. As with those trials, it's important to keep the distinction clear: RGN-137 is full-length Tβ4 applied topically, not the injectable Tβ4(17-23) fragment sold as TB-500. The two share a mechanism in broad strokes but are chemically different products tested in entirely different ways.

RGN-137's proposed mechanism in EB specifically goes a step beyond general wound-closure speed: researchers have reported that it may help upregulate laminin-5 (also called laminin-332), a structural protein involved in anchoring skin layers together that is defective or absent in some forms of EB. If accurate, that would make RGN-137's relevance to EB somewhat more targeted than a generic wound-healing effect — though this remains a proposed mechanism from the sponsor's own research rather than an independently confirmed finding.

---

What the Trials Actually Tested

Phase 2 (NCT00311766). RegeneRx ran an early-phase trial evaluating RGN-137's effect on wound healing in patients with EB, testing the topical gel against a vehicle (inactive gel) control. Public reporting at the time highlighted case-level results — including at least one enrolled patient described as achieving complete wound healing during the trial — but individual patient outcomes reported in press releases are not the same as a completed trial's statistically powered efficacy result, and this should be read as an early, encouraging signal rather than a proven effect.

Phase 3 (NCT03578029). Years later, RegeneRx's licensee (GtreeBNT) received FDA clearance to proceed with a Phase 3 trial specifically for junctional and dystrophic EB — the two more severe subtypes — designed as a larger, randomized, multi-center, double-blind, placebo-controlled study intended to enroll around 200 patients across U.S. clinical sites. Progressing from Phase 2 to an FDA-cleared Phase 3 design is a meaningful marker: it means regulators found the earlier safety and preliminary efficacy data sufficient to justify a much larger, more rigorous trial, which doesn't happen automatically.

As of the most recent public information, this program represents the most clinically advanced human trial history for any thymosin beta-4-based product tested specifically in a genetic skin disease — a distinct research track from the ophthalmic (RGN-259) and cardiac (RGN-352) programs covered in this site's human clinical trials overview.

---

How Seriously Should This Be Taken?

Genuinely more seriously than most of the animal and cell-culture research covered elsewhere on this site, for a few concrete reasons:

It's human trial data, not a rodent or cell-culture model. EB is a disease with obvious, visible wounds that are straightforward to assess for closure, size, and pain — an easier condition to measure a real effect in than something like tendon strength.

It advanced through FDA-cleared trial phases rather than stalling at an early preclinical stage, which is not true of the large majority of TB-500-related research topics on this site.

The patient population has a specific, unmet medical need. EB has no cure and limited treatment options, which is part of why a therapy with even a modest effect on wound closure would be clinically meaningful.

That said, a few caveats matter just as much:

Efficacy data from the Phase 3 trial has not been broadly published in detail as of this writing — the strongest public signal remains the Phase 2 case reports and the fact that the program advanced.

No thymosin beta-4 product has yet reached FDA approval for EB or any other indication, despite more than a decade of trial activity across RegeneRx's various formulations.

This says nothing about injectable TB-500. RGN-137 is a topical, full-length-protein gel applied directly to open EB wounds under clinical supervision — not a systemic injection, and not the fragment sold in research-chemical channels.

---

Why This Doesn't Generalize to Injectable TB-500

| Factor | RGN-137 (EB trials) | Injectable TB-500 |
|---|---|---|
| Molecule | Full-length thymosin beta-4 | Synthetic Tβ4(17-23) fragment |
| Route | Topical gel, applied directly to open wounds | Subcutaneous or intramuscular injection |
| Evidence level | Human Phase 2 data, Phase 3 trial cleared by FDA | Almost entirely animal and cell-culture studies |
| Population studied | Patients with a specific genetic skin disease | No equivalent human population studied |
| Regulatory status | Investigational, trial-stage | Research chemical, not evaluated for any use |

The pattern here matches what shows up across this site's other human-trial coverage — the ophthalmic dry eye and corneal research is a close parallel: real clinical trials exist for thymosin beta-4, but they consistently involve a different formulation and route than the injectable product most TB-500 research discussion actually centers on. It's a genuine data point about the underlying peptide's biological activity in humans — not evidence about what a self-administered injection does systemically.

---

What's Genuinely Unknown

Whether the Phase 3 trial has completed and what its detailed efficacy results showed — public updates on RegeneRx's later-stage EB program are less frequent and less detailed than the earlier Phase 2 reporting.

Whether the proposed laminin-5 upregulation mechanism is confirmed as the actual driver of any clinical effect, as opposed to a more general wound-healing and anti-inflammatory contribution.

Whether any EB-specific formulation will ultimately reach approval, given the broader pattern of RegeneRx's Tβ4 pipeline advancing through trials over many years without a marketed product yet.

---

Frequently Asked Questions

Is RGN-137 the same as TB-500?

No. RGN-137 contains full-length thymosin beta-4 in a topical gel formulation. TB-500 is the shorter synthetic Tβ4(17-23) fragment, sold through research-chemical channels and typically used by injection. They share the same underlying actin-regulation mechanism but are different molecules tested in entirely different ways.

Has a thymosin beta-4 treatment for epidermolysis bullosa been FDA-approved?

Not as of this writing. RGN-137 has advanced through Phase 2 trials and received FDA clearance for a Phase 3 trial design in junctional and dystrophic EB, which is a meaningful regulatory milestone, but no thymosin beta-4 product currently holds FDA approval for EB or any other indication.

Could injectable TB-500 help someone with epidermolysis bullosa?

There's no research supporting that. The EB trials used a topical gel formulation of full-length Tβ4 applied directly to wounds under clinical supervision, not an injected fragment. EB is also a serious genetic condition requiring management by specialists experienced with the disease, not a self-directed research protocol.

What makes the EB trial data more notable than most TB-500 research?

It's one of the few places in the entire thymosin beta-4 literature where a product actually reached human clinical trials in the specific patient population it's meant to help, and advanced far enough to receive FDA clearance for a large Phase 3 design. Most TB-500-related research discussed elsewhere on this site is still animal or cell-culture work.

Why would a peptide studied for tendons and skin also be relevant to a genetic skin disease?

Because EB's core clinical problem — skin that blisters and fails to heal normally from routine friction — is fundamentally a wound-healing problem, even though its root cause is genetic rather than traumatic. Any compound with a documented effect on keratinocyte migration and inflammation, the same mechanism studied in TB-500's other wound research, was a logical candidate to test in a disease defined by chronic, non-healing wounds.

Sourcing Quality Research Peptides

The EB trial history belongs to RGN-137, not to injectable TB-500 — a distinction worth keeping in mind when evaluating any vendor or forum claim that leans on this clinical data. For researchers working with the standard injectable form, Apollo Peptide Sciences provides third-party tested, research-grade TB-500 with published certificates of analysis.

---